One serious side effect of the PD-1/PD-L1 checkpoint blockade therapies using antibodies is inducing type-1 diabetes because T cells also attack the pancreatic cells whose PD-L1 is blocked53,54. This evidence concerns the gene PDCD1 and type 1 diabetes mellitus.